We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Capillary and Venous Lactate Compared in ED Patients

By LabMedica International staff writers
Posted on 16 Apr 2019
Print article
Image: The Automatic QC RAPID Systems RAPIDPoint 500 blood gas analyzer (Photo courtesy of Siemens Healthcare).
Image: The Automatic QC RAPID Systems RAPIDPoint 500 blood gas analyzer (Photo courtesy of Siemens Healthcare).
Elevated lactate levels are a common finding in acutely unwell patients. Blood lactate level is a good predictor of patient outcome and high lactate levels are associated with high morbidity and mortality. Lactate may be detected and measured in all blood samples: arterial, venous and capillary.

Currently, blood lactate can be measured formally in the laboratory, using blood gas analyzers or with handheld devices. Strong correlations have been shown between blood lactate levels in samples analyzed in the central laboratory, by blood gas analyzers and handheld devices. Capillary blood lactate testing with handheld analyzers has great advantages to reduce the time needed for clinical decisions, and for extended use in the prehospital setting.

Emergency department (ED) personnel at the Chinese University of Hong Kong (Shatin, Hong Kong) and their colleagues carried out a prospective observational study of patients presenting to the ED of Prince of Wales Hospital (Shatin, Hong Kong) and 240 patients (mean age 69.9 years) were recruited. Venous and capillary blood samples were collected for lactate analysis. Venous blood samples (approximate 1 mL) were collected by venipuncture while capillary blood samples were collected by finger-prick with a disposable lancet.

Venous lactate levels were measured by blood gas analyzer the Siemens Automatic QC RAPID Systems RAPIDPoint 500 (VL-Ref) served as the reference standard. Capillary lactate levels were immediately analyzed by two handheld lactate analyzers: Nova StatStrip Xpress Lactate Meter (CL-Nova) and Lactate Scout+ (CL-Scout). Venous lactate levels were also measured on the two handheld lactate analyzers. All lactate measurements were performed within 15 minutes after obtaining the venous sample.

The scientists reported that the results of VL-Ref ranged from 0.70 to 5.38 mmol/L (mean of 1.96 mmol/L). Regarding capillary lactate measurements, the bias (mean difference) between VL-Ref and CL-Scout+ was −0.22 with 95% limits of agreement (LOA) of −2.17 to 1.73 mmol/L and the bias between VL-Ref and CL-Nova was 0.46, with LOA of −1.08 to 2.00 mmol/L. For venous lactate, results showed the bias between VL-Ref and VL-Scout+ were 0.22 with LOA being −0.46 to 0.90 mmol/L, and the bias between VL-Ref and VL-Nova was 0.83 mmol/L with LOA −0.01 to 1.66 mmol/L.

The author concluded that their study shows poor agreement between capillary lactate and reference values. The study does not support the clinical utility of capillary lactate point-of-care testing (POCT). However, venous lactate measured by Scout+ handheld analyzer may have potential for screening patients who may need further testing. The study was published on April 3, 2019, in the journal BMJ OPEN.

Related Links:
Chinese University of Hong Kong
Prince of Wales Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.